Saturday, October 31, 2026

USD/CNH Bullish Momentum With A 1% Jump In The Last 21 Sessions

ViaNews Editorial Team

September 11, 2023

USD/CNH Bullish Momentum With A 1% Jump In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.73% for the last 21 sessions. At 04:08 EST on Monday, 11 September, USD/CNH (USDCNH) is $7.30.

USD/CNH's yearly highs and lows, it's 0.147% up from its 52-week low and 0.822% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be oversold (<=20).

News about

  • Eur/usd struggles to hold gains, set for weekly loss as it trades below 1.0700. According to FXStreet on Saturday, 9 September, "The EUR/USD is trading at 1.0699, registering minuscule gains of 0.03%, set to finish the week with losses of 0.69%.", "On the other hand, if the EUR/USD finishes the week above 1.0700, an upward correction is expected, with buyers eyeing the 1.0750 area, followed by the September 5 high at 1.0798."
  • Eur/usd: weekly forecast 10th September - 16th September - 10 September 2023. According to DailyForex on Sunday, 10 September, "Nervous sentiment remains a factor in current EUR/USD trading and the broad markets in general. ", "The lower price value of the EUR/USD reflects what other major currency pairs teamed against the USD are also experiencing."
  • Eur/usd posts modest gains around 1.0725 amid the weaker usd, investors await US cpi, ECB rate decision. According to FXStreet on Monday, 11 September, "The EUR/USD pair recovers some lost ground around 1.0725 after bouncing off the low of 1.0697. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com